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The epigenetic signature of subcutaneous fat
cells is linked to altered expression of genes
implicated in lipidmetabolism in obesewomen
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Abstract
Background: Obesity is associated with changes in fat cell gene expression and metabolism. What drives
these changes is not well understood. We aimed to explore fat cell epigenetics, i.e., DNA methylation, as one
mediator of gene regulation, in obese women. The global DNA methylome for abdominal subcutaneous fat
cells was compared between 15 obese case (BMI 41.4 ± 4.4 kg/m2, mean ± SD) and 14 never-obese control
women (BMI 25.2 ± 2.5 kg/m2). Global array-based transcriptome analysis was analyzed for subcutaneous white
adipose tissue (WAT) from 11 obese and 9 never-obese women. Limma was used for statistical analysis.
Results: We identified 5529 differentially methylated DNA sites (DMS) for 2223 differentially expressed genes
between obese cases and never-obese controls (false discovery rate <5 %). The 5529 DMS displayed a
median difference in beta value of 0.09 (range 0.01 to 0.40) between groups. DMS were under-represented in
CpG islands and in promoter regions, and over-represented in open sea-regions and gene bodies. The 2223
differentially expressed genes with DMS were over-represented in key fat cell pathways: 31 of 130 (25 %)
genes linked to “adipogenesis” (adjusted P = 1.66 × 10−11), 31 of 163 (19 %) genes linked to “insulin signaling”
(adjusted P = 1.91 × 10−9), and 18 of 67 (27 %) of genes linked to “lipolysis” (P = 6.1 × 10−5). In most cases,
gene expression and DMS displayed reciprocal changes in obese women. Furthermore, among 99 candidate
genes in genetic loci associated with body fat distribution in genome-wide association studies (GWAS); 22
genes displayed differential expression accompanied by DMS in obese versus never-obese women (P = 0.0002),
supporting the notion that a significant proportion of gene loci linked to fat distribution are epigenetically
regulated.
Conclusions: Subcutaneous WAT from obese women is characterized by congruent changes in DNA
methylation and expression of genes linked to generation, distribution, and metabolic function of fat cells.
These alterations may contribute to obesity-associated metabolic disturbances such as insulin resistance in
women.
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Background
Obesity is linked to metabolic complications including
insulin resistance (IR) and type 2 diabetes (T2D). Adi-
posity and development of systemic IR are associated
with an interrelated set of adaptions in white adipose
tissue (WAT). The ability of catecholamines, the major
lipolytic hormones in man, to stimulate lipolysis is
blunted in obese subjects [1]. Furthermore, the turn-
over of adipocyte lipids is decreased in obesity [2].
These metabolic alterations may retain lipids in fat cells
and thereby contribute to WAT mass expansion. In
addition, the morphology of WAT can influence fat cell
lipolysis [3]. Thus as reviewed [4], a phenotype charac-
terized by few but large adipocytes (hypertrophy) is
linked to IR.
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The cellular adaption of WAT to adiposity is
accompanied by major changes in gene expression reflect-
ing both metabolic adaptions of the fat cells, and changes
in the tissue as a whole, e.g., fibrosis and inflammation
[5, 6]. Through large genome-wide association studies
(GWAs), a number of susceptibility genes for obesity
and related metabolic disturbances have been mapped,
but together they explain no more than a minor pro-
portion of the heritability/variation in these pheno-
types, and the culprit genes are in most cases unknown
[7–10].
Epigenetic modifications, such as DNA methylation
and histone modifications, constitute an additional layer
regulating gene expression and thus effecting pheno-
types and the development of various states of disease
[11]. DNA methylation mainly occurs in the context of
CG dinucleotides (CpGs) and has traditionally been
associated with gene repression [12]. Global DNA
methylomes of human subcutaneous WAT have been
related to BMI, body fat distribution, weight loss, and
T2D [13–17]. In general, the reported absolute differ-
ences in DNA methylation at specific CpG sites between
groups have been small, from a few percent up to 10 %
[14, 16], and with few exceptions not systematically re-
lated to gene expression (e.g., [14, 17, 18]).
The interpretation of differences in DNA methyla-
tion profiles for tissues is complicated by the fact that
the epigenetic profile can differ substantially between
various cell types within a tissue [19]. WAT contains
many different cell types of which adipocytes comprise
only 20–40 % [16]. Thus, the DNA methylome of non-
fat cells can mask differentially DNA methylated sites
(DMS) in fat cells. In addition, obesity is associated
with altered cellular composition of WAT, e.g., infil-
tration with inflammatory cells [20]. Changes in the
WAT DNA methylome may therefore reflect altered
cellular composition rather than true DMS in a spe-
cific cell type. In a recent study, we performed DNA
methylation profiling on isolated fat cells in order to
avoid the confounding effect of mixed cell populations
[21]. We compared post-obese women investigated
2 years after bariatric surgery with never-obese con-
trols and reported a number of epigenetic changes in
fat cell DNA methylation. In the present study, we
report fat cell epigenetic signatures and WAT global
transcriptome profiles in obese cases and never-obese
control women in order to define DMS that could
regulate fat cell gene expression and metabolic adap-
tion to obesity. We report that several genes in path-
ways involved in adipogenesis, insulin signaling, and
lipolysis display DMS accompanied by differential
gene expression in obese women. Furthermore, candi-
date genes for fat distribution identified through
GWAs are enriched for DMS.
Results
Clinical characteristics of subjects
Clinical characteristics of the included cohorts are detailed
in Table 1. Compared with the never-obese controls, the
obese individuals displayed significantly higher BMI,
plasma insulin, HOMA-IR, triglycerides and diastolic
blood pressure. Although systolic blood pressure displayed
a trend to be higher in the obese group, the difference was
not significant. Finally, the mean fat cell volume was
significantly larger in the obese cases than the never-
obese controls. There was no significant difference in
age between the groups.
In the subset of samples used for global transcrip-
tome analysis, the mean BMI among the 11 obese
cases was 42 ± 5 kg/m2 and in the never-obese con-
trols 25 ± 2 kg/m2. The mean age in both groups was
49 years. The subjects included for global transcrip-
tome analysis did not differ significantly in phenotype
from their corresponding overall group. In the valid-
ation cohort, the mean BMI among the 24 obese cases
was 40 ± 7 kg/m2 and in the 25 never-obese controls,
24 ± 2 kg/m2. The mean age in both groups was
43 years.
Table 1 Clinical characteristics of subjects
Never-obese Obesea Pb
n 14 15
Age (years) 45 ± 11 46 ± 11 0.93
Weight (kg) 69 ± 7 115 ± 11 3.4 × 10−13
BMI (kg/m2) 25.2 ± 2.5 41.4 ± 4.5 4.1 × 10−12
Waist to hip ratio 0.85 ± 0.06 0.98 ± 0.06 5.0 × 10−6
Systolic blood
pressure (mmHg)
123 ± 19 138 ± 22 0.073
Diastolic blood
pressure (mmHg)
74 ± 6 85 ± 9 6.0 × 10−4
P-Glucose (mmol/l) 5.1 ± 0.4 5.7 ± 1.2 0.053
P-Insulin (mU/l) 4.6 ± 2.3 16.0 ± 10.3 3.7 × 10−4
P-Cholesterol (mmol/l) 4.7 ± 1.0 4.9 ± 0.7 0.57
P-HDL Cholesterol
(mmol/l)
1.5 ± 0.4 1.1 ± 0.3 0.0058
P-Triglycerides (mmol/l) 0.86 ± 0.72 1.67 ± 0.92 0.013
P-NEFA (mmol/l) 0.57 ± 0.17 0.83 ± 0.16 2.4 × 10−4
P-Apolipoprotein B (g/l) 0.83 ± 0.25 0.96 ± 0.25 0.19
P-Apolipoprotein A1 (g/l) 1.39 ± 0.22 1.19 ± 0.24 0.028
Mean fat cell volume (pl) 443 ± 169 994 ± 184 5.5 × 10−9
aThree of the obese women had type 2 diabetes, of which two were treated
with diet plus metformin, and one woman with diet alone. Nine were treated
for hypertension and one patient had stable multiple sclerosis and did not
receive any drugs
bComparison of control and obese group with unpaired t test. Values
are mean ± SD
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Global pattern of adipocyte CpG methylation in
never-obese and obese women
The average degree of DNA methylation, i.e., the aver-
age beta value for the 319,596 analyzed probes, was
higher in fat cells from obese cases (0.425 ± 0.366,
mean ± SD) as compared to never-obese controls
(0.420 ± 0.375) (P = 1.3 × 10−7). The average level of
DNA methylation stratified by genome region in rela-
tion to CpG content and functional parts of genes is
shown in Fig. 1. The average DNA methylation of CpG
sites located in open seas, CpG islands, and surround-
ing shore regions was significantly higher in obese as
compared to never-obese women whereas no signifi-
cant difference was observed in shelf regions. The
average DNA methylation of CpG sites located in 5′
regions of genes and in gene bodies was significantly
higher in obese cases as compared to never-obese con-
trols, whereas there was no significant difference in the
1st exons and 3′UTR regions. The mean within-region
absolute difference in DNA methylation between groups
was small, in all cases less than 1 %.
Among 319,596 analyzed CpG sites, there were
32,724 DMS in fat cells between obese cases versus
never-obese controls according to Limma and applying
a FDR <1 % (Additional file 1: Table S1). We focused
the subsequent analysis on the 23,576 DMS linked to
genes. Global transcriptome analysis identified 3878
differentially expressed genes in WAT between obese
cases and never-obese controls applying thresholds FDR
5 % and fold change 20 % (Additional file 1: Table S2);
2546 of these genes were expressed at higher levels in
obese women. We did not have enough material to
perform transcriptome analysis on isolated fat cells.
However, since the expression of genes involved in me-
tabolism often display enriched expression in fat cells
as compared to stroma cells, we believe that the WAT
transcriptome data provide valid information about
differential gene expression of relevance also for fat
cells. Next, we compared the 23,576 DMS with the
3878 differentially expressed genes and identified 5529
DMS associated with 2223 differentially expressed
genes between obese cases and never-obese controls
(Additional file 1: Table S3). The 5529 DMS displayed
a median difference in beta value of 0.09 (range 0.01 to
0.40) between the obese cases and never-obese con-
trols. The genomic distribution of the 5529 DMS, as
compared to all 319,596 analyzed probes, is shown in
Fig. 2 in relation to CpG content and functional parts
of genes. DMS were under-represented in CpG islands
and over-represented in open sea-regions. DMS were
under-represented in promoter regions (TSS1500,
TSS200) and over-represented in gene bodies. We
related CpG methylation at individual DMS to gene ex-
pression (Table 2). DMS with inverse association to gene
expression were modestly (58 %) over-represented in the
5′ regions of genes (i.e., TSS1500, TSS200, 5′UTR,
and first exon) as compared to DMS with directionally
consistent change in DNA methylation and expression
comparing obese versus never-obese women. DMS in
gene bodies and 3′UTR regions displayed an equal
Fig. 1 DNA methylation landscape in obese cases versus never-obese control women. After filtering 319,596 CpG probes were mapped to
genome regions based on Illumina annotation. We calculated the average level of DNA methylation within the obese (black bars) and
never-obese (hatched bars) groups stratified on genome region in relation to CpG content (left), and functional gene regions (right).
TSS1500; within 1500 basepairs of transcriptional start site (TSS). TSS200; within 200 basepairs of TSS. *P < 0.05; **P < 0.01
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distribution of negative and positive associations be-
tween DNA methylation and gene expression.
DMS in insulin signaling, adipogenesis, and lipolysis
pathways
The 2223 differentially expressed genes associated with
DMS were analyzed for over-representation of specific
WikiPathways as compared to all genes in the human gen-
ome using Webgestalt. The most significantly over-
represented pathways include focal adhesion, immune
response, adipogenesis, and insulin signaling (Table 3). Of
particular interest, 31 of 130 (25 %) of genes linked to
“adipogenesis” displayed DMS and differential gene
expression (adjusted P = 1.66 × 10−11); the corresponding
proportion for “insulin signaling” was 31 of 163 (19 %)
(adjusted P = 1.91 × 10−9), and for “fatty acid biosynthesis”
12 of 29 (41 %) (adjusted P = 3.99 × 10−8). Gene expression
levels and DNA methylation status for a selection of genes
in these pathways are shown in Table 4. A detailed list can
be found in Additional file 1: Table S4. In most cases, dif-
ferential gene expression and DMS display reciprocal
changes in obese compares to control women, e.g., expres-
sion of PPARG and PPARGC1A was lower in obese
women compared to controls whereas multiple CpG sites
in these genes, in particular in the promoter regions
(TSS1500), displayed higher methylation in the obese
women compared to controls.
Fat cell lipolysis is a key pathway to examine for epi-
genetic impact since dysregulated fat cell lipolysis has
been inked to both increased fat storage, via blunted
catecholamine-induced lipolysis, and IR by enhanced
spontaneous (basal) lipolysis. The lipolysis pathway is
not listed as a pathway in public databases and was there-
fore not included in the analysis above. We defined in the
following analysis, genes included in the lipolytic pathway
as the genes listed in the comprehensive review by Lafon-
tan and Langin [22]. Among 67 lipolysis genes, 18 dis-
played differential expression and DMS between obese and
never-obese women (P = 6.1 × 10−5). Lipolysis genes with
DMS are shown in Table 5 and include ABHD5 (the coac-
tivator of ATGL), ADCY2, ADRB1, CIDEA, and PLIN2.
The list of 5529 DMS accompanied with differential ex-
pression contains 120 cross-reactive probes (Additional
file 1: Table S3). We have not applied any filter based on
detection P values. If we apply a cutoff filter P < 0.01 on
the list of 5529 DMS, 24 CpG sites do not pass the test.
There were no cross-reactive probes in the list of DMS
linked to candidate pathways, e.g., adipogenesis, lipolysis,
Fig. 2 Genomic distribution of DMS between obese and never-obese women in relation to CpG content (left) and functional parts of genes
(right). The genomic distribution of 5529 DMS between obese and never-obese women (black bars) (FDR 1 %) were compared to all
319,596 analyzed CpG probes (hatched bars). TSS1500; within 1500 basepairs of transcriptional start site (TSS). TSS200; within 200 basepairs
of TSS









aInverse association between DNA methylation and gene expression in obese
versus never-obese women
bDNA methylation and gene expression display same directionally consistent
change in obese versus never-obese women
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and insulin signaling. One probe (cg10543624 in PPARA)
had detection P > 0.01.
DMS of candidate genes in genetic loci linked to
adiposity in GWAS
Next, we investigated if candidate genes in genetic
loci linked to adiposity in GWAS displayed evidence
of epigenetic regulation. Among 150 candidate protein
coding genes in 97 genetic loci associated with BMI [10],
20 genes displayed differential expression accompanied by
DMS in obese women compared to controls which was
slightly more than expected (P = 0.045) (Additional file 1:
Table S5). Furthermore, among 99 protein coding candi-
date genes in 69 genetic loci associated with body fat dis-
tribution [9], 22 genes displayed differential expression
accompanied by DMS in obese versus never-obese control
women (P = 0.0002). Candidate genes for body fat distri-
bution with DMS in this study included ADAMTS9,
ARL15, C5, CMIP, CPEB4, EYA1, FAM13A, FGF2, GMDS,
HLA-DRA, KCNJ2, KLHL31, LY86, MAP3K1, MSC,
NLRP3, PEMT, PLCG2, PPARG, TBX15, TFPI, and VEGFA
(Additional file 1: Table S6).
Comparison with DMS in other cohorts
Finally, we examined if the 32,724 obesity-associated DMS
in fat cells detected in the present study were identified in
WAT in separate cohorts. Among all 32,724 DMS, 1474
sites had been assayed in WAT from an independent set
of obese and non-obese women using the Illumina 27K
array. Ninety of 1474 CpG sites were differentially methyl-
ated between obese and non-obese women (P < 0.05, one-
sided test); for 66 of 90 DMS the association was
directionally consistent with the results on the 450K array
(Additional file 1: Table S7; Additional file 2: Figure S1).
The mean absolute level of methylation at specific
CpG sites, measured as beta value, differed substantially
between fat cells (450K array) and WAT (27K array); this
could be due to differences in methylation between fat
cells and WAT stroma cells. This is supported by the fact
that the absolute difference in DNA methylation at spe-
cific CpG sites between obese versus non-obese women
tend to be larger in fat cells as compared to WAT.
We also mapped the 32,724 DMS from the present
study to a number of reported DNA methylation profiling
studies on WAT applying the 450K platform. Benton MC
et al. identified 3601 DMS before versus after weight loss
induced by bariatric surgery [16]. Importantly, 1239 DMS
described by Benton et al. overlapped with the present
study of which 1236 CpG sites displayed directionally con-
sistent difference in methylation in the comparisons
before versus after weight loss, and obese versus never-
obese women (Additional file 1: Table S8; Additional file 2:
Figure S2). Rönn et al. identified 39,533 CpG sites whose
methylation in WAT of women associated with BMI. BMI-
associated CpG sites (8079) overlap with the present study
of which 7876 displayed directionally consistent difference
in methylation (Additional file 1: Table S9) [17]. Fur-
thermore, Nilsson et al. identified 15,627 DMS in WAT
associated with T2D [14]. DMS (2885) overlapped with
the present study, of which 2630 DMS displayed direc-
tionally consistent difference in methylation in T2D
and obesity (Additional file 1: Table S10) [14]. Overall,
the performed comparisons with three other independ-
ent analyses support the accuracy of our assay.
Table 3 Pathways enriched for differentially expressed genes with DMS
Number of genes
Wikipathway Observed Expected Total Adjusted P
Focal adhesion 47 9.25 185 1.52 × 10−18
Adipogenesis 31 6.5 130 1.66 × 10−11
Regulation of toll-like receptor signaling 33 7.7 154 4.77 × 10−11
Integrated Pancreatic Cancer Pathway 35 9.05 181 1.73 × 10−10
MAPK signaling pathway 33 8.25 165 2.12 × 10−10
B Cell Receptor Signaling Pathway 26 5.7 114 1.21 × 10−9
TCR Signaling Pathway 25 5.3 106 1.21 × 10−9
Insulin Signaling 31 8.15 163 1.91 × 10−09
Muscle cell TarBase 55 21.21 424 1.91 × 10−09
Regulation of Actin Cytoskeleton 30 7.85 157 3.00 × 10−09
DNA damage response 22 4.38 89 2.97 × 10−09
Integrin-mediated cell adhesion 23 4.97 101 6.25 × 10−09
AGE-RAGE pathway 19 3.74 76 3.36 × 10−08
IL-3 Signaling Pathway 16 2.66 54 3.68 × 10−08
Fatty Acid Biosynthesis 12 1.43 29 3.99 × 10−08
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Average SD Average SD Average SD Average SD
Adipogenesis
KLF15 143 41 253 54 0.57 4.78E−04 cg00540067 5′UTR 0.53 0.09 0.35 0.06 0.18 6.01E−05
cg27639142 5′UTR 0.33 0.08 0.18 0.06 0.15 1.94E−04
cg01031983 Body 0.25 0.07 0.13 0.04 0.12 4.85E−05
cg21468971 Body 0.84 0.06 0.92 0.02 −0.08 2.32E−04
cg14339848 3′UTR 0.47 0.05 0.37 0.05 0.10 9.90E−04
KLF5 33 4 45 9 0.73 5.16E−03 cg09338033 1stExon 0.06 0.02 0.04 0.01 0.02 1.89E−04
cg14281591 Body 0.87 0.06 0.92 0.02 −0.05 6.75E−03
PLIN2 506 102 408 53 1.24 3.62E−02 cg03885527 Body 0.84 0.04 0.9 0.03 −0.06 4.18E−03
PPARA 105 13 147 25 0.72 5.54E−04 cg10543624 Body 0.74 0.09 0.86 0.05 −0.12 2.31E−04
PPARG 1607 142 2096 258 0.77 4.08E−04 cg01412654 TSS1500 0.47 0.08 0.33 0.06 0.14 1.87E−04
cg18063278 TSS1500 0.28 0.09 0.15 0.05 0.13 7.36E−04
cg25929976 TSS1500 0.24 0.07 0.13 0.04 0.11 1.21E−04
cg16827534 5′UTR 0.31 0.13 0.15 0.05 0.16 7.11E−04
cg16197186 5′UTR 0.91 0.03 0.84 0.05 0.07 2.62E−04
cg10499651 Body 0.23 0.11 0.09 0.02 0.14 8.70E−05
PPARGC1A 58 9 96 31 0.61 2.36E−03 cg11270806 TSS1500 0.18 0.09 0.08 0.02 0.10 3.66E−04
cg27461259 TSS1500 0.35 0.07 0.16 0.04 0.19 5.36E−06
cg27514608 TSS1500 0.21 0.11 0.08 0.02 0.13 6.43E−05
Insulin signaling
AKT2 1021 104 1302 205 0.78 3.57E−03 cg14309246 TSS1500 0.23 0.09 0.13 0.03 0.10 5.03E−03
cg25333225 TSS1500 0.17 0.05 0.11 0.02 0.06 9.61E−04
cg13351352 Body 0.35 0.12 0.18 0.07 0.17 6.22E−04
cg15153957 3′UTR 0.14 0.13 0.06 0.02 0.08 4.54E−03
INSR 192 19 244 42 0.79 6.85E−03 cg00428638 Body 0.29 0.09 0.16 0.08 0.13 3.34E−03
cg09779027 Body 0.33 0.09 0.16 0.05 0.17 3.99E−05
cg10148591 Body 0.25 0.08 0.13 0.03 0.12 2.11E−04
cg23845936 Body 0.63 0.08 0.43 0.08 0.20 4.44E−05
IRS1 121 24 181 63 0.67 3.46E−02 cg00727310 1stExon 0.35 0.09 0.2 0.04 0.15 1.03E−04
cg04129548 1stExon 0.39 0.09 0.22 0.07 0.17 1.88E−04
cg13008631 1stExon 0.36 0.07 0.17 0.06 0.19 1.11E−05
cg04751089 3′UTR 0.14 0.07 0.04 0.02 0.10 1.20E−05
cg00305996 3′UTR 0.55 0.13 0.3 0.11 0.25 1.78E−04
IRS2 115 19 184 28 0.62 2.99E−05 cg25312054 1stExon 0.67 0.09 0.49 0.08 0.18 1.24E−04
cg03337886 1stExon 0.37 0.07 0.21 0.06 0.16 2.99E−05
cg10488031 1stExon 0.35 0.03 0.25 0.05 0.10 1.17E−03
cg05514401 1stExon 0.69 0.09 0.57 0.09 0.12 1.00E−02
cg01569664 Body 0.49 0.12 0.31 0.08 0.18 6.38E−03
cg12085119 Body 0.53 0.08 0.34 0.09 0.19 9.22E−05
cg13539803 Body 0.92 0.03 0.95 0.01 −0.03 2.83E−03
cg20445402 Body 0.76 0.14 0.44 0.11 0.32 2.45E−05
cg24526103 Body 0.29 0.14 0.11 0.04 0.18 7.59E−04
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Discussion
Herein we describe the global methylome of isolated hu-
man fat cells in relation to adiposity. We find that obes-
ity is associated with a large number of DMS. In
particular, several genes in the adipogenesis, insulin sig-
naling, and lipolysis pathways display DMS accompanied
by differential gene expression comparing obese and
control women. Furthermore, candidate genes for fat
distribution from GWAS are enriched for DMS in this
study.
The global pattern of DMS in the genome reported here
is consistent with, and complements, findings that previ-
ously have been reported for human WAT, which contains
a number of cell types besides fat cells. We observed a
slightly higher global mean DNA methylation in obese
women, while Benton et al. have reported significantly
higher DNA methylation before compared to after weight
loss for all gene regions in subcutaneous WAT [16]. This
implies that higher DNA methylation in obese is second-
ary to obesity and reversed upon weight loss. In agree-
ment with this, we observe higher DNA methylation in
obese women when comparing the global fat cell DNA
methylome pattern between obese (present study) and
post-obese women [21]. The relative fat cell turnover rate
is not affected by obesity [23] and it is therefore unlikely
that differences in fat cell age explain DNA hypermethyla-
tion in obese women. The absolute difference in global
DNA methylation between groups was small, but in
the same order of magnitude as observed in other
studies [16, 21]. Future studies are needed to deter-
mine the functional significance of observed changes in
global DNA methylation.
The genomic distribution of DMS, i.e., relatively few
near CpG islands and in the promoter regions, and over-
representation in open sea-regions is in agreement with
what has been reported in WAT in relation to physical
exercise and T2D [18, 24]. CpG sites displaying inverse
correlations between DNA methylation and expression
of associated genes were over-represented in promoter
and 5′ regions of genes, whereas CpG sites showing
positive correlations between DNA methylation and ex-
pression of associated genes were over-represented in
Table 4 Selected differentially expressed genes with DMS in adipogenesis, insulin signaling, and fatty acid biosynthesis pathways
(Continued)
cg25924746 Body 0.39 0.13 0.16 0.06 0.23 3.97E−05
SGK2 265 46 208 57 1.28 3.45E−02 cg04420889 TSS1500 0.44 0.16 0.2 0.1 0.24 1.11E−03
cg21685427 TSS1500 0.36 0.08 0.26 0.06 0.10 3.13E−03
cg06600331 TSS200 0.39 0.07 0.29 0.06 0.10 4.91E−03
cg06796271 TSS200 0.26 0.11 0.11 0.03 0.15 1.18E−04
SLC2A4 120 27 304 85 0.39 5.34E−06 cg03670302 3′UTR 0.78 0.06 0.65 0.1 0.13 1.38E−03
Fatty acid biosynthesis
ACACA 206 38 301 83 0.69 4.23E−03 cg01760189 TSS1500 0.51 0.11 0.31 0.08 0.20 1.83E−04
cg20778688 TSS1500 0.69 0.09 0.53 0.07 0.16 3.11E−04
cg07375836 5′UTR 0.19 0.04 0.13 0.06 0.06 8.52E−03
cg16822666 5′UTR 0.19 0.08 0.08 0.04 0.11 3.98E−04
cg06026545 Body 0.14 0.07 0.08 0.02 0.06 3.65E−03
cg07834934 Body 0.65 0.05 0.72 0.05 −0.07 5.96E−03
cg08013737 Body 0.43 0.1 0.29 0.07 0.14 3.07E−03
cg15939920 Body 0.87 0.05 0.92 0.02 −0.05 1.48E−03
cg26100256 Body 0.83 0.05 0.72 0.03 0.11 4.43E−05
ACACB 1765 158 2720 440 0.65 1.88E−05 cg12178147 TSS1500 0.47 0.13 0.21 0.08 0.26 2.81E−05
cg23921871 1stExon 0.59 0.09 0.46 0.08 0.13 5.87E−03
cg06002638 Body 0.49 0.08 0.36 0.05 0.13 8.85E−04
ACLY 428 66 773 494 0.55 3.41E−02 cg19443920 TSS1500 0.12 0.06 0.06 0.01 0.06 1.50E−03
cg12641024 5′UTR 0.37 0.16 0.17 0.05 0.20 1.09E−03
cg14583225 5′UTR 0.34 0.09 0.18 0.06 0.16 8.03E−05
cg27470486 5′UTR 0.13 0.08 0.06 0.03 0.07 2.61E−03
cg01761362 Body 0.37 0.16 0.16 0.07 0.21 6.64E−04
PECR 392 64 597 120 0.66 5.14E−04 cg10881745 Body 0.71 0.09 0.44 0.09 0.27 1.02E−05
aAdjusted P comparing groups in Limma (in DNA methylation analysis adjusting for age)
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Av. SD Av. SD Av. SD Av. SD
ABHD5 808 64 1327 343 0.61 9.76E−05 cg24595152 Body 0.57 0.06 0.4 0.1 0.17 2.04E−04
ADCY2 24 6 34 8 0.71 1.08E−02 cg07176385 Body 0.69 0.07 0.6 0.05 0.09 9.27E−03
cg27629673 Body 0.78 0.07 0.86 0.04 −0.08 8.43E−03
cg12378867 3′UTR 0.27 0.1 0.16 0.05 0.11 4.90E−03
ADCY6 302 36 381 53 0.79 3.62E−03 cg22689690 TSS1500 0.04 0.02 0.02 0.01 0.02 1.61E−03
cg00160359 5′UTR 0.78 0.06 0.7 0.04 0.08 2.89E−03
cg11661914 5′UTR 0.26 0.09 0.14 0.05 0.12 1.33E−03
cg24092939 5′UTR 0.18 0.1 0.07 0.03 0.11 8.58E−04
cg25196508 5′UTR 0.28 0.13 0.11 0.07 0.17 1.12E−03
cg26266429 Body 0.19 0.07 0.1 0.07 0.09 8.53E−04
ADCY7 108 18 63 19 1.72 1.76E−04 cg23580000 1stExon 0.86 0.07 0.93 0.03 −0.07 1.85E−03
cg16548911 Body 0.58 0.08 0.68 0.07 −0.1 6.66E−03
ADRB1 57 16 79 23 0.72 2.80E−02 cg13848598 1stExon 0.2 0.07 0.1 0.03 0.1 7.02E−04
cg14826456 1stExon 0.08 0.03 0.05 0.02 0.03 1.45E−03
CIDEA 164 44 567 187 0.29 1.01E−06 cg14976646 TSS1500 0.08 0.03 0.05 0.01 0.03 1.34E−03
cg19883905 TSS1500 0.05 0.02 0.03 0.01 0.02 4.68E−03
cg14923652 3′UTR 0.93 0.03 0.85 0.04 0.08 4.32E−05
CIDEC 1857 174 2597 265 0.71 2.42E−05 cg03604278 TSS1500 0.3 0.09 0.14 0.02 0.16 1.20E−05
cg07222243 5′UTR 0.28 0.07 0.13 0.05 0.15 3.13E−05
EDNRA 327 78 463 116 0.71 9.64E−03 cg17073859 TSS1500 0.48 0.05 0.37 0.04 0.11 1.27E−04
cg00379467 TSS200 0.23 0.07 0.12 0.04 0.11 5.01E−04
cg00974629 TSS200 0.38 0.07 0.25 0.04 0.13 7.57E−05
cg05618426 TSS200 0.26 0.09 0.13 0.02 0.13 9.82E−05
EDNRB 618 61 488 81 1.27 3.57E−03 cg07974719 TSS1500 0.31 0.06 0.24 0.03 0.07 9.57E−03
cg12983394 TSS1500 0.05 0.04 0.02 0.01 0.03 5.52E−03
cg12120741 1stExon 0.29 0.06 0.19 0.04 0.1 3.77E−04
cg18210860 Body 0.24 0.12 0.1 0.03 0.14 3.35E−04
GNG7 78 14 112 21 0.69 9.31E−04 cg01286319 5′UTR 0.53 0.1 0.67 0.07 −0.14 1.64E−03
cg02309655 5′UTR 0.3 0.08 0.19 0.04 0.11 6.22E−03
cg06371583 5′UTR 0.26 0.06 0.19 0.04 0.07 8.78E−03
cg08461840 5′UTR 0.54 0.11 0.71 0.09 −0.17 7.26E−04
cg11906607 5′UTR 0.33 0.1 0.21 0.07 0.12 3.69E−03
cg13078421 5′UTR 0.09 0.05 0.04 0.01 0.05 3.72E−04
cg18229071 5′UTR 0.54 0.07 0.64 0.05 −0.1 1.81E−03
cg18754118 5′UTR 0.34 0.07 0.25 0.03 0.09 2.71E−03
cg19382697 5′UTR 0.77 0.05 0.84 0.03 −0.07 1.03E−03
cg19853565 5′UTR 0.15 0.13 0.05 0.02 0.1 1.74E−03
cg20091384 5′UTR 0.24 0.07 0.16 0.03 0.08 5.42E−03
cg22023664 5′UTR 0.76 0.09 0.88 0.02 −0.12 2.35E−04
cg24874003 5′UTR 0.2 0.12 0.07 0.03 0.13 7.32E−04
cg27176392 5′UTR 0.92 0.02 0.87 0.03 0.05 1.28E−03
IL6R 141 16 103 13 1.36 1.47E−04 cg24346686 TSS1500 0.13 0.04 0.09 0.03 0.04 7.89E−03
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gene bodies and 3′UTRs, which is in agreement with the
literature on WAT epigenetics [24]. In fact, whereas DNA
methylation traditionally has been considered to be a re-
pressor of gene expression, methylation of CpG sites in
gene bodies often show a positive correlation with active
transcription [25]. Previous WAT DNA methylome stud-
ies report smaller absolute difference in methylation at
specific CpG sites between clinical groups compared to
what we observe in fat cells. The median delta-beta was
0.09 in the present study, whereas the delta-beta rarely
was larger than 5 % in WAT between T2D and healthy
controls [24]. Twenty-two CpG sites had delta-beta >20 %
after versus before weight loss, whereas 773 CpG sites
reached this threshold in the present study [16]. It is pos-
sible that differences are due to that we investigate isolated
fat cells, whereas previous studies were performed on
WAT pieces, which contain a number of additional cell
types besides the fat cells. The latter may also explain the
limited overlap with reported DMS associated with adi-
posity or responding to weight loss [13, 15, 16].
Are the observed variations in DMS of biological sig-
nificance? Although we did not perform direct molecu-
lar studies, our findings when comparing DMS with
gene expression suggest a pathophysiological role. We
report over-representation of DMS accompanied by dif-
ferential expression in genes in key fat cell pathways
such as adipogenesis, insulin signaling, and lipolysis. In
most cases, adipogenesis, insulin signaling, and lipolysis
genes were lower expressed in obese as compared to
never-obese control women. Blunted lipolytic response
has been linked to obesity [1]. WAT hypertrophy is as-
sociated with IR and has been linked to dysregulation of
adipogenesis [26]. These pathways are known to be dys-
regulated in WAT of obese individuals, but the up-
stream regulation is poorly understood. Our results
support the notion of epigenetic dysregulation of adipo-
genesis, insulin signaling, and lipolysis pathways being
present in obese women. Numerous studies have
highlighted the importance of epigenetic regulation of adi-
pogenesis in vitro (reviewed in [27]). As far as we know,
Table 5 Lipolysis genes displaying differentially expression accompanied by DMS in obese women compared to controls
(Continued)
cg04437762 Body 0.67 0.07 0.82 0.05 −0.15 1.94E−05
cg17001401 Body 0.31 0.08 0.15 0.05 0.16 4.73E−05
cg25135018 Body 0.76 0.09 0.88 0.05 −0.12 5.63E−04
INSR 192 19 244 42 0.79 6.85E−03 cg00428638 Body 0.29 0.09 0.16 0.08 0.13 3.34E−03
cg09779027 Body 0.33 0.09 0.16 0.05 0.17 3.99E−05
cg10148591 Body 0.25 0.08 0.13 0.03 0.12 2.11E−04
cg23845936 Body 0.63 0.08 0.43 0.08 0.2 4.44E−05
NPR1 265 41 374 44 0.71 2.21E−04 cg07106989 Body 0.9 0.02 0.81 0.04 0.09 4.62E−05
PDE3B 701 119 972 169 0.72 2.00E−03 cg03439703 TSS1500 0.17 0.04 0.11 0.02 0.06 3.83E−04
cg18222865 TSS1500 0.34 0.06 0.2 0.05 0.14 1.10E−04
cg21901307 TSS1500 0.1 0.03 0.06 0.01 0.04 1.12E−03
cg12177909 Body 0.31 0.1 0.19 0.05 0.12 2.74E−03
PDE5A 118 14 90 17 1.31 3.31E−03 cg15191465 TSS1500 0.05 0.01 0.03 0.01 0.02 2.68E−03
cg19191984 TSS1500 0.08 0.02 0.05 0.01 0.03 3.78E−03
cg06531595 Body 0.78 0.05 0.71 0.03 0.07 2.47E−03
PLIN2 506 102 408 53 1.24 3.62E−02 cg03885527 Body 0.84 0.04 0.9 0.03 −0.06 4.18E−03
PPARG 1607 142 2096 258 0.77 4.08E−04 cg01412654 TSS1500 0.47 0.08 0.33 0.06 0.14 1.87E−04
cg18063278 TSS1500 0.28 0.09 0.15 0.05 0.13 7.36E−04
cg25929976 TSS1500 0.24 0.07 0.13 0.04 0.11 1.21E−04
cg16197186 5′UTR 0.91 0.03 0.84 0.05 0.07 2.62E−04
cg16827534 5′UTR 0.31 0.13 0.15 0.05 0.16 7.11E−04
cg10499651 Body 0.23 0.11 0.09 0.02 0.14 8.70E−05
PRKAR2B 1956 324 2467 178 0.79 3.69E−03 cg03661844 Body 0.95 0.03 0.79 0.11 0.16 5.45E−06
cg10691109 Body 0.1 0.06 0.04 0.01 0.06 9.79E−05
cg26104690 Body 0.77 0.08 0.66 0.07 0.11 3.64E−03
Av average
a Adjusted P comparing groups in Limma (in DNA methylation analysis adjusting for age)
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we here provide the first evidence for epigenetic regulation
of fat cell lipolysis. Lipolysis is believed to promote fat
storage, whereas epigenetic regulation of all three path-
ways could contribute to obesity-associated insulin resist-
ance. There is some overlap in pathways with DMS
reported in the present study and those previously re-
ported to display differential DNA methylation in re-
sponse to weight loss, e.g., focal adhesion, and
adipogenesis, suggesting that epigenetic dysregulation of
these pathways could be reversed upon weight loss [16].
A recent study showed the value of epigenetics as a
complement to GWAS to pinpoint candidate genes
harboring susceptibility alleles for T2D [28]. Recently,
numerous new genetic loci linked to fat distribution
have been mapped [9]. Candidate genes in these loci
have been shown to display enriched expression in
WAT as compared to other organs and have implied
that adipogenesis and insulin signaling pathways are
involved in the regulation of fat distribution. Our
results complement these findings. We show a strong
over-representation of fat cell DMS accompanied by
differential gene expression of candidate genes for fat
distribution. Among these genes, PPARG, TBX15, and
PEMT have previously been implicated in adipogenesis
and VEGFA as well as FGF2 in angiogenesis [9].
One limitation of the present study is that gene ex-
pression was performed on WAT specimen, since we did
not have sufficient amounts of isolated fat cells for glo-
bal transcriptome analysis. Genes involved in fat cell
metabolic regulation are usually overexpressed in fat
cells as compared to the stroma [5]. Furthermore, we
did compare differentially expressed genes in adipocyte
pathways in the present study with results from Lee YH
et al. who performed global transciptome profiling on
adipocytes from obese and non-obese Pima Indians [29].
Their array had limited coverage and they used a very
stringent threshold to define differentially expressed
genes. Among 85 genes in adipocytes pathways in the
present study, 17 were also differentially expressed in
the study by Lee YH et al. (EDNRB, GNG7, NPR1,
PDE3B, PRKAR2B, AGPAT2, IRS2, LMNA, NR3C1,
NRIP1, EIF4EBP1, ACACB, ECHS1, FASN, HADH,
PC, PECR). Genes overlapping between the studies all
showed a directionally consistent change. This con-
firms that genes in adipocyte pathways are differen-
tially expressed in fat cells of obese compared to lean
subjects.
Conclusions
In conclusion, DMS accompanied by differential expres-
sion in genes linked to fat distribution and fat cell me-
tabolism may contribute to abdominal fat storage and
obesity-associated IR in women.
Methods
Subjects and clinical evaluation
Clinical data are presented in Table 1. Fifteen obese
women (BMI >30 kg/m2) and 14 never-obese healthy
control women (BMI <30 kg/m2) were recruited in asso-
ciation with planned visits to our surgical units for gas-
tric by-pass surgery because of obesity and through local
advertisement for the purpose of studying WAT factors
regulating body weight. Data not shown herein on
never-obese women have been reported elsewhere [21].
Four never-obese and 4 obese women were menopausal.
All 14 never-obese women were healthy. Three of the
obese women had T2D, out of which two were treated
with diet and metformin, and one subject with diet
alone. Nine of the obese individuals were treated for
hypertension. One patient had stable mild multiple scler-
osis but did not receive any treatment for this indication.
The women undergoing gastric by-pass surgery partici-
pated in a trial on the effect of bariatric surgery
(NCT01785134 at www.clinicaltrials.gov).
Transcriptome analysis on WAT specimens was con-
ducted for 20 of the above individuals (11 obese and 9
never-obese). For remaining subjects included in this
study, we did not have sufficient amount of WAT for
transcriptome analysis.
For validation of DMS in an independent cohort, we
studied 24 obese otherwise healthy and 25 non-obese
healthy women, who have been described previously
[30]. The validation was performed on DNA from WAT
specimens since we did not have isolated fat cells from
this cohort.
Ethics and consent
The study was approved by the Regional Ethics Committee
in Stockholm (2003/326) and all subjects gave their written
informed consent to participation.
Clinical evaluation and WAT sampling
Participants were investigated at 8 AM after an overnight
fast. Anthropometric measurements (height, weight, waist
and hip circumference, blood pressure) were performed
and followed by a venous blood sample. Blood glucose
and lipids were analyzed at the hospital’s routine chemis-
try laboratory. Plasma insulin was measured by ELISA
(Mercodia, Uppsala, Sweden) as previously described [31].
Biopsies from the subcutaneous abdominal WAT were
obtained by needle aspiration under local anesthesia.
WAT samples were thoroughly rinsed in sodium chlor-
ide (9 mg/ml).
Handling of WAT samples and isolation of fat cells
From WAT samples, we isolated the fat cell fraction ac-
cording to the collagenase procedure [32]. Mean fat cell
volume was determined as previously described [33].
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Briefly, in adipocyte suspensions, we measured cell sizes
by direct microscopy and the mean adipocyte diameter
was calculated from measurements of 100 cells. Since adi-
pocytes are spherical in shape, cell volume can be esti-
mated from the diameter. From adipose specimens, 200 μl
of packed isolated fat cells and/or 300 mg unfractio-
nated WAT pieces were frozen in liquid nitrogen and
kept at −70 °C for subsequent DNA (cells) or RNA (tissue)
preparation.
DNA preparation
Genomic DNA was prepared from fat cells using the
QiAamp DNA Mini kit (cat no. 51304, Qiagen, Hilden,
Germany). The DNA purity and quality was confirmed
by A260/280 ratio >1.8 on a Nanodrop ND-1000 Spec-
trophotometer (Thermo Fisher Scientific Inc., Waltham,
MA, US). The DNA concentration was measured by
Qubit (Life technologies, Stockholm, Sweden).
DNA methylation microarray assays
DNA methylation was analyzed in DNA extracted
from fat cells using the Infinium Human Methylation
450 BeadChip assay (Illumina, San Diego, CA, USA).
Genomic DNA (500 ng) was bisulfite treated using the EZ
DNA methylation kit (Zymo Research, Orange, CA, USA)
with the alternative incubation conditions recommended
when using the Infinium Methylation Assay. The methyla-
tion assay was performed on 4 μl bisulfite-converted gen-
omic DNA at 50 ng/μl according to the Infinium HD
Methylation Assay protocol (Part #15019519, Illumina).
For validation of DMS in the independent cohort,
bisulphite converted DNA from WAT specimens was
hybridized to the Illumina Infinium 27K Human Methyla-
tion Beadchip v1.2 using standardized protocols (Illu-
mina). DNA methylation data have been deposited in the
National Center for Biotechnology Information Gene Ex-
pression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/
geo) and are accessible using GEO series accession num-
bers GSE67024 and GSE24884, respectively. The methyla-
tion assays were done at BEA (www.bea.ki.se).
DNA methylation microarray: bioinformatic analyses
BeadChip images were captured using the Illumina
iScan. The raw methylation score for each probe repre-
sented as a methylation beta value was calculated using
the GenomeStudio Methylation module software
(2010.3) [34]. All included samples showed high-quality
bisulfite conversion according to Zymo control samples
and also passed all GenomeStudio quality control steps
based on built in control probes for staining,
hybridization, extension, and specificity. For the Infi-
nium Human Methylation 450 BeadChip arrays, we
next applied the Bioconductor Lumi package to per-
form color and quantitative normalization of the
DNA methylation data. The BMIQ package was used
to adjust the beta values of type 2 design microarray
probes into a statistical distribution characteristic of
type 1 probes. Beta values were converted to
M values [M = log2(beta/(1 − beta))], a statistically
more valid method for conducting differential methy-
lation analysis. As the beta value is easier to interpret
biologically, M values were reconverted to beta values
when describing the results.
The Infinium Human Methylation 450 BeadChip
array contains 485,577 probes, which covers 21,231
(99 %) of RefSeq genes. Probes overlapping SNPs can
interfere with hybridization. Probes (88,464) containing
common SNPs with minor allele frequency (MAF) >10 %
according to Illumina were therefore excluded. A fur-
ther 77,517 CpG probes with SNPs within 10 base-
pairs from the interrogated CpG sites were excluded.
This last filtering step was motivated by our observa-
tion that these probes were threefold enriched among
probes that displayed the largest variation (standard
deviation) in DNA methylation between samples. It is
possible that the presence of SNPs inferred with
probe hybridization and quantification of DNA
methylation. Following the filtering steps, 319,596
probes were taken forward to identify DMS. We used
Webgestalt to identify Wikipathways over-represented
with DMS as compared to all genes in the human
genome [35].
Transcriptome microarray assay
WAT specimens (100 mg) were disrupted mechanically.
From high-quality total RNA, we prepared and hybridized
biotinylated complementary RNA to Gene 1.1 ST Arrays,
and then washed, stained, and scanned the arrays using
standardized protocols (Affymetrix Inc., Santa Clara, CA,
USA). The microarray hybridizations were done at BEA
(www.bea.ki.se). Subsequent data analyses were performed
using the Affymetrix Expression Console version 1.1. The
Robust Multi-array analysis algorithm was used for data
normalization and calculation of gene expression. To
allow comparisons of transcript levels between samples,
all samples were subject to an all-probeset scaling-to-
target signal of 100.
Among the 33,297 probesets on the Gene 1.1 ST array,
we filtered for the 22,371 probesets annotated with a
gene symbol. Following exclusion of uncharacterized
transcripts labeled LOC or Flj, 21,534 probesets were
taken forward for subsequent analysis of differentially
expressed genes. When multiple probesets represented
the same gene, we show results for the probeset with the
highest call; the results (P values and fold change in ex-
pression) are very similar independently of which probe-
set is used.
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Statistical analysis
We used the Bioconductor package Limma on methyla-
tion M values to identify DMS between obese and
never-obese women, adjusting for age which is known to
influence DNA methylation, and applying the thresholds
false discovery rate (FDR) 1 %; we chose a stringent
threshold here to avoid false positive [36, 37]. We also
used Limma to compare gene expression between the
obese and never-obese groups. In transcriptome analysis,
we used the thresholds FDR 5 % and fold change 20 %
since our experience from previous studies is that by ap-
plying these thresholds we can confirm the results by
quantitative PCR. Unpaired t test was applied to com-
pare average global DNA methylation between the obese
and never-obese groups, and in analysis of specific DMS
in the validation cohorts.
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